GUARD — Guard Therapeutics International AB (publ) Share Price
- SEK295.45m
- SEK241.26m
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 7.78 | ||
Price to Tang. Book | 7.78 | ||
Price to Free Cashflow | n/a | ||
Price to Sales | n/a | ||
EV to EBITDA | n/a |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | -262.87% | ||
Return on Equity | -183.51% | ||
Operating Margin | n/a |
Financial Summary
Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | SEKm | n/a | n/a | n/a | n/a | n/a | n/a | 285.5 | n/a |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Guard Therapeutics International AB (publ), formerly A1M Pharma AB, is a Sweden-based company, which is active within the healthcare sector. The Company conducts development and commercialization of treatment and diagnostics based on the alpha-1-microglobulin (A1M) protein. The protein serves as a radical inhibitor, an antioxidant, a protector against free hemoglobin and a tissue repairer. A1M is a candidate for different therapeutic and diagnostic uses, such as alleviation of autoimmune diseases and stroke treatment. The Company works with the protein and conducts research at the Biomedical Center in Lund University, Sweden. The Company develops a drug for intravenous treatment of preeclampsia, a condition that can occur during pregnancy and can contribute to premature deliveries.
Directors
- Cristina Glad CHM (67)
- Tobias Larsson Agervald CEO
- Torun Labedzki CFO
- Elisabeth Augustsson OTH (55)
- Lars Hockenstrom OTH
- Fredrik Lehmann OTH (44)
- Ann-Kristin Myde OTH (66)
- Ronny Renfurm OTH
- Michael Reusch OTH
- Sara Thuresson OTH
- Peter Gilmour MGB
- Goran Forsberg DRC (56)
- Johannes Hulthe DRC
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- April 4th, 2008
- Public Since
- April 3rd, 2013
- No. of Employees
- 5
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
OMX Nordic Exchange Stockholm
- Shares in Issue
- 22,130,778

- Address
- Guard Therapeutics, Nybrogatan 34, 2 tr, STOCKHOLM, 114 39
- Web
- https://guardtherapeutics.com/
- Phone
- +46 86706551
- Contact
- Ingmar Rentzhog
- Auditors
- PricewaterhouseCoopers AB
Upcoming Events for GUARD
Q1 2025 Guard Therapeutics International AB (publ) Earnings Release
Guard Therapeutics International AB (publ) Annual Shareholders Meeting
Q2 2025 Guard Therapeutics International AB (publ) Earnings Release
Similar to GUARD
2cureX AB
OMX Nordic Exchange Stockholm
Acousort AB
OMX Nordic Exchange Stockholm
Active Biotech AB publ
OMX Nordic Exchange Stockholm
Alligator Bioscience AB
OMX Nordic Exchange Stockholm
AlzeCure Pharma AB
OMX Nordic Exchange Stockholm
FAQ
As of Today at 20:58 UTC, shares in Guard Therapeutics International AB (publ) are trading at SEK13.35. This share price information is delayed by 15 minutes.
Shares in Guard Therapeutics International AB (publ) last closed at SEK13.35 and the price had moved by -53.29% over the past 365 days. In terms of relative price strength the Guard Therapeutics International AB (publ) share price has underperformed the FTSE Global All Cap Index by -54.46% over the past year.
The overall consensus recommendation for Guard Therapeutics International AB (publ) is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreGuard Therapeutics International AB (publ) does not currently pay a dividend.
Guard Therapeutics International AB (publ) does not currently pay a dividend.
Guard Therapeutics International AB (publ) does not currently pay a dividend.
To buy shares in Guard Therapeutics International AB (publ) you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of SEK13.35, shares in Guard Therapeutics International AB (publ) had a market capitalisation of SEK295.45m.
Here are the trading details for Guard Therapeutics International AB (publ):
- Country of listing: Sweden
- Exchange: STO
- Ticker Symbol: GUARD
Based on an overall assessment of its quality, value and momentum Guard Therapeutics International AB (publ) is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Guard Therapeutics International AB (publ) is SEK60.00. That is 349.44% above the last closing price of SEK13.35.
Analysts covering Guard Therapeutics International AB (publ) currently have a consensus Earnings Per Share (EPS) forecast of -SEK7.92 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Guard Therapeutics International AB (publ). Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -38.48%.
As of the last closing price of SEK13.35, shares in Guard Therapeutics International AB (publ) were trading -40.08% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Guard Therapeutics International AB (publ) PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at SEK13.35.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Guard Therapeutics International AB (publ)'s management team is headed by:
- Cristina Glad - CHM
- Tobias Larsson Agervald - CEO
- Torun Labedzki - CFO
- Elisabeth Augustsson - OTH
- Lars Hockenstrom - OTH
- Fredrik Lehmann - OTH
- Ann-Kristin Myde - OTH
- Ronny Renfurm - OTH
- Michael Reusch - OTH
- Sara Thuresson - OTH
- Peter Gilmour - MGB
- Goran Forsberg - DRC
- Johannes Hulthe - DRC